Hep Email Update Global Fatty Liver Day Promotes Liver Disease Screening [VIDEO] This year’s theme, “Act Now, Screen Today,” urged people to screen for MASLD, which often shows no symptoms. Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hep D People who used the combination regimen were more likely to still have an undetectable HDV load a year after stopping treatment. Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis A second PPAR agonist, seladelpar, has also done well in clinical trials and is under FDA review. Advertisement Hepatitis C Survey Tell us about your experience with hepatitis C. What Is Hepatitis C? Get the basics! What Is Fatty Liver Disease? (MASLD and MASH) Learn the latest about fatty liver. Advertisement Science News Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024 Armored CAR-T Therapy Shows Promise for Liver Cancer Newsfeed New Effort to Include People With HIV or on PrEP in Clinical Trials [VIDEO] Global Fatty Liver Day Promotes Liver Disease Screening [VIDEO] UT Health Awarded Grants for MASLD Research EASL Congress 2024: Combating Liver Disease Collectively Science News Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024 Armored CAR-T Therapy Shows Promise for Liver Cancer Newsfeed New Effort to Include People With HIV or on PrEP in Clinical Trials [VIDEO] Global Fatty Liver Day Promotes Liver Disease Screening [VIDEO] UT Health Awarded Grants for MASLD Research EASL Congress 2024: Combating Liver Disease Collectively

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@hepmag.com. Please remember to add update@hepmag.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: